Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Keith Kaye

General ID · RU

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View

Dr. Robert Schooley

General ID · UCSD

View

Dr. Priya Nori

General ID · MMC

View

Dr. Jan Patterson

General ID · UTHSCSA

View

Dr. Kavita Bhavan

General ID · Dallas County Hospital District

View

Dr. John Goldman

General ID · UPMC Central PA

View

Dr. Gonzalo Bearman

General ID · Medical College of Virginia

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Implementation of two-stage testing for Clostridioides difficile at a tertiary referral veterans hospital.

    Jun 4, 2026DOI: 10.1017/ash.2026.10427Journal ArticleASHE

    Written by: Madeline MarkerDimitri Drekonja

    Find these authors on Roon

    DD
    Dr. Dimitri Drekonja
    General ID · Minneapolis VA

    Introduction

    Clostridioides difficile infection (CDI) is a common cause of diarrhea in US hospitals, affecting ∼1% of hospitalized patients each year.1 This translates to 453,000 cases/year, 83,000 recurrences, and 29,300 deaths,2 with estimated costs of $1 to $4.9 billion annually.3The prevalence and morbidity of CDI make accurate diagnosis and treatment essential. Manifestations range from asymptomatic carriage to mild to severe diarrhea, toxic megacolon, and pseudomembranous colitis.2 In the 2000s, highly sensitive polymerase chain reaction (PCR) stool testing for the gene encoding C. difficile toxin B became widely adopted as a stand-alone test.1,4 However, some patients with positive PCR results (PCR+) had few signs of infection, and when tested for toxin B by enzyme-linked immune assay (ELISA), results were often negative (PCR+/Tox−).1 PCR+/Tox− patients had similar outcomes to patients with diarrhea who were PCR−. PCR+/Tox+ patients have worse outcomes.1 This observation, and the increase in CDI diagnoses when stand-alone PCR testing was instituted, led to the hypothesis that PCR testing identified colonization with C. difficile capable of producing toxin B, but without toxin production. Treatment of carriers confers no known benefit and may be harmful.5 Accordingly, two-stage testing has been increasingly used,6 whereby all PCR+ samples receive a confirmatory toxin test, with results reported as PCR−, PCR+/Tox−, or PCR+/Tox+.The Minneapolis Veterans Affairs Health Care System (MVAHCS) implemented two-stage testing for CDI in July 2022 with the expectation that it would decrease unnecessary treatment of PCR+/Tox− patients based on prior studies demonstrating no detectable harm. This study evaluates the impact of two-stage testing on patient management (antibiotic use) and outcomes (symptom resolution, CDI-related complications, ICU care, or death).

    Methods

    We performed a retrospective review of adult veterans with PCR+ stool samples for C. difficile at the MVAHCS from 7/1/2022 to 9/17/2025. Testing was performed via a platform only for CDI (Cepheid) or testing for multiple bacterial, viral, and protozoal infections (BioFire). Testing was at provider discretion, with guidance in the ordering menu reminding clinicians that testing is appropriate for patients not on laxatives, without another known cause of diarrhea, and at least three diarrheal stools/day. Formed stools were declined per laboratory policy. Only the first positive test per patient was included. All PCR+ stool samples were tested for toxin using an ELISA-based stool antigen test; PCR− samples received no further testing. PCR+ results were reported immediately. Toxin results released ∼60 minutes later. The study protocol was reviewed by the MVAHCS Institutional Review Board (IRB) and categorized as quality improvement exempt from oversight.
    Record review was performed by a single person (MM) and discussed with a second team member (DD). Abstracted data included demographic information, age-adjusted Charlson Comorbidity Index (CCI), date of CDI symptom onset, lab values, stool consistency and count, stool testing results, selection and duration of antimicrobials treating CDI, and details of non-CDI antimicrobials. Treatment response and outcomes data included symptom resolution, repeat CDI testing and treatment, CDI-related complications (ie, megacolon and colectomy for fulminant colitis), death within 30 days, and need for ICU-level care.
    Statistical analysis was performed based on toxin status. Baseline characteristics, treatment, and outcomes were compared between groups. A P-value of <.05 was considered significant.

    Results

    Two hundred and forty participants had a PCR+ sample, 83 (34.6%) PCR+/Tox+, and 157 (65.4%) PCR+/Tox− (Table 1). PCR+/Tox+ participants typically had an initial white blood cell count ≥15,000 or <4,000 (40.5% vs 21.8%; P = .04) (Table 1). There were no significant between-group differences for other lab values (Table 1). Loose stool on the day of PCR testing was similar between groups (75.9% vs 65.0%; P = .11) (Table 1).
    PCR+/Tox+ participants were significantly more likely to receive antibiotics (98.8% vs 51.3%; P < .001) (Table 2). Fidaxomicin was the most common treatment (61.0% vs 56.4%; P = .63). Mean treatment was 10 days for both groups.
    Symptom resolution was similar (78.3% vs 77.1%; P = .87). PCR+/Tox+ participants had a higher rate of CDI-related complications (4.8% vs 0.6%; P = .04) (Table 2). Complication rates did not differ between PCR+/Tox− participants who received antibiotics and those who did not (0.6% vs 0%; P = .5) (Table 2). Death or need for ICU care was similar (3.6% vs 6.4%; P = .55) and (7.2% vs 8.9%; P = .81), respectively (Table 2).
    There was no significant difference in participants who received repeat CDI testing within 14 days (1.2% vs 5.7%; P = .17). Of those retested, 0 PCR+/Tox+ versus 2 PCR+/Tox− were PCR+/Tox+ on repeat testing (P = 1.0). Only 3 of 9 (33.0%) initially PCR+/Tox− underwent treatment, all with fidaxomicin.
    PCR+/Tox+ participants were more likely to undergo repeat testing within 15–30 days (15.7% vs 2.6%; P = .0003). Of those tested, toxin positive rates were similar (53.9% vs 50.0%; P = 1.0). Both participants initially PCR+/Tox− but subsequently PCR+/Tox+ on retesting were treated with vancomycin, compared to 3/7 PCR+/Tox+ (100% vs 42.9%; P = .4).
    Some participants from both cohorts were treated empirically for recurrent symptoms without CDI testing (6.0% vs 2.5%; P = .30).

    Discussion

    Most participants with PCR+ results for C. difficile lacked detectable toxin (65.4%), highlighting the clinical ambiguity in identifying patients to test. Symptoms are non-specific (abdominal pain, fever, and loose stool). Loose stool was reported at testing in participants with and without detectable toxin (Table 1). Participants with Tox+ results were more likely to have abnormalities in their WBC count, while other laboratory markers for illness severity were similar (Table 1).
    Toxin testing significantly influenced CDI treatment. Nearly all PCR+/Tox+ participants received treatment (98.8%) versus 51.2% of PCR+/Tox− participants (Table 2). PCR+/Tox+ participants had a higher rate of CDI-related complications (4.8% vs .6%) (Table 2), suggesting they differ from PCR+/Tox− participants. Despite only 51.2% of PCR+/Tox− participants receiving treatment, complication rates did not differ between those who received antibiotics (.6%) and those who did not (0%). Additionally, the majority in both cohorts reported symptom resolution (78.4% vs 77.1%) (Table 2). This aligns with prior literature finding no increase in adverse events when withholding antibiotics in Tox− patients.7,8 The implementation of two-stage testing identified a large proportion of PCR+/Tox− participants, half of whom did not receive treatment, without signal of harm. This suggests two-stage testing can identify a population that may not have CDI and be managed with supportive cares.
    These findings have clinical implications. The sensitivity of PCR testing allows detection of patients with small amounts of C. difficile genetic material, with studies demonstrating higher CDI diagnosis rates with PCR testing.1 Treatment of patients with colonization increases antimicrobial use, disrupts the microbiome, and potentially increases CDI rates.5 Although 51% of PCR+/Tox− patients still received treatment, 49% (77 individuals) were spared treatment without discernable harms. Transition to two-stage testing was accompanied by limited education, largely via reminders of appropriate test ordering within the medical record. Limitations include the retrospective and single-center nature of this study, and that participants were largely White, male, and non-Hispanic/Latino.
    Table 1.Comparison of demographic and initial laboratory data on date of PCR testing between PCR+/Tox+ and PCR+/Tox− cohortsTable 1 long description.Demographic and laboratory dataPCR+/Tox+(n = 83)PCR+/Tox−(n = 157)Median age (IQR)74 (67,78)74 (63,79)Female sex, No. (%)5 (6.0)18 (11.5)White race, No. (%)69 (83.1)127 (80.9)Not Hispanic or Latino, No. (%)75 (90.4)146 (93)Median CCI (IQR)5 (4,8)5 (3,7)WBC count ≥ 15,000 or <4,000 when symptoms developed, No./No. tested (%)17/42 (40.5)19/87 (21.8)Cr level > 1.5, No./No. tested (%)6/39 (15.4)25/89 (28.1)Albumin, No./No. tested (%)2/24 (8.3)7/58 (12.1)Diarrhea present at testing, No. (%)63 (75.9)102 (65.0)Median stool count at testing (IQR)3 (2.75,5.25)3 (2,5)A table comparing demographic and laboratory data between PCR/Tox and PCR/Tox cohorts, including age, sex, race, ethnicity, CCI, WBC count, Cr level, albumin, diarrhea presence, and stool count.Note. No., number; IQR, interquartile range.*P ≤ .05.
    Comparison of demographic and initial laboratory data on date of PCR testing between PCR+/Tox+ and PCR+/Tox− cohorts
    Table 1 long description.
    Demographic and
    laboratory data
    Note. No., number; IQR, interquartile range.
    P ≤ .05.
    Table 2.Comparison of treatment modalities and patient outcomes between the PCR+/Tox+ and PCR+/Tox− cohortsTable 2 long description.Treatment modalities and patient outcomesPCR+/Tox+ (n = 83)PCR+/Tox−(n = 157)Treatment with typical antibiotics (oral vancomycin, fidaxomicin, or metronidazole), No. (%)82 (98.8)78 (52.3)Use of non C. difficile antibiotic, No. (%)30 (36.1)53 (33.8)Symptom resolution, No. (%)65 (78.3)121 (77.1)Median duration of diarrhea after treatment days (IQR)7 (4,17)5 (2,10.5)CDI-related complications, No. (%)4 (4.8)1 (.6)Death within 30 days of treatment, No. (%)3 (3.6)10 (6.4)ICU-level care, No. (%)6 (7.2)14 (8.9)A table comparing treatment modalities and patient outcomes between PCR/Tox and PCR/Tox cohorts.Note. No., number.P ≤ .05.P* < .001.
    Comparison of treatment modalities and patient outcomes between the PCR+/Tox+ and PCR+/Tox− cohorts
    Table 2 long description.
    Note. No., number.
    P ≤ .05.
    P < .001.
    DDDr. Dimitri Drekonja

    Dr. Dimitri Drekonja

    Infectious Disease · General Infectious Disease
    Minneapolis VA Medical Center
    dimitri